<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055897</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02</org_study_id>
    <nct_id>NCT03055897</nct_id>
  </id_info>
  <brief_title>Tear Film Innovations iLux Safety Study</brief_title>
  <official_title>Tear Film Innovations iLux Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tear Film Innovations, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tear Film Innovations, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measure the change in the temperature of the cornea and surrounding eye tissue temperature
      immediately after heating the eyelids with the iLux device using the protocol treatment
      profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2016</start_date>
  <completion_date type="Actual">May 18, 2016</completion_date>
  <primary_completion_date type="Actual">May 17, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal and surrounding eye lid tissue temperature</measure>
    <time_frame>1 hour</time_frame>
    <description>Change from baseline to post-procedure</description>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events (%)</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of discomfort/pain based on study questionnaire (scale 1-10)</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of ocular surface staining</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in keratometry (diopter)</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in manifest refraction (diopter)</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in BSCVA (# of letters)</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in intraocular pressure (mm Hg)</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>iLux 2020 System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meibomian Gland Heating</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iLux 2020 System</intervention_name>
    <description>Application of heat to the meibomian glands to determine potential impact on eyes and surrounding tissue.</description>
    <arm_group_label>iLux 2020 System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years and older of any gender or race

          2. Provision of subject written informed consent prior to study participation

        Exclusion Criteria:

          1. History of ocular surgery including intraocular, oculo-plastic, corneal or refractive
             surgery within 1 year

          2. Ocular trauma or herpetic keratitis within the previous 3 months

          3. Cicatricial lid margin disease identified via slit lamp examination

          4. Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal
             infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids
             including a hordeolum or stye)

          5. Active ocular inflammation or history of chronic, recurrent ocular inflammation within
             prior 3 months (e.g. retinitis, macular inflammation, choroiditis, uveitis, iritis,
             scleritis, episcleritis keratitis)

          6. Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical
             burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal
             fluorescein staining, or map dot fingerprint dystrophy

          7. Lid surface abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm,
             lagophthalmos, severe trichiasis, severe ptosis) that affect lid function in either
             eye

          8. Grade 3 or 4 meibomianitis, and/or blepharitis on a scale of 0 to 4

          9. Women who are pregnant, nursing, or not utilizing adequate birth control measures

         10. Individuals using another investigational device or agent within 30 days of study
             participation

         11. Body temperature above 37Â°C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Encinitas Optometry</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92924</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

